Negotiations are ongoing in New York to agree the latest UN political declaration on non-communicable diseases (NCDs) and ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

This review examines AI and ML's role in transforming thermoelectric materials design, focusing on defect engineering and ...